NGL Fine-Chem (NSE:NGLFINE) Scaled Net Operating Assets: N/A (As of Mar. 2026)


NSE:NGLFINE NGL Fine-Chem Ltd NSE:NGLFINE
78 GF Score
Price ₹3,206.00
GF Value ₹2,815.72
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is NGL Fine-Chem Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NGL Fine-Chem's operating assets for the quarter that ended in Mar. 2026 was ₹4,995 Mil. NGL Fine-Chem's operating liabilities for the quarter that ended in Mar. 2026 was ₹1,078 Mil. NGL Fine-Chem's Total Assets for the quarter that ended in Dec. 2025 was ₹0 Mil. Therefore, NGL Fine-Chem's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.


NGL Fine-Chem Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for NGL Fine-Chem's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NGL Fine-Chem Scaled Net Operating Assets Chart

NGL Fine-Chem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.98 0.73 0.84 0.82 0.90

NGL Fine-Chem Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:NGLFINE vs LLY, JNJ, ABBV: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGL Fine-Chem Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where NGL Fine-Chem's Scaled Net Operating Assets falls into.


NSE:NGLFINE
78GF Score
NGL Fine-Chem Ltd NSE:NGLFINE
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NGL Fine-Chem Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NGL Fine-Chem's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(4994.73-1077.61)/4333.913
=0.90

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5454.958 - 460.228
=4994.73

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2162.663 - 564.033 - 521.02
=1077.61

NGL Fine-Chem's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(4994.73-1077.61)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5454.958 - 460.228
=4994.73

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2162.663 - 564.033 - 521.02
=1077.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?

Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued. The current stock price of ₹3,206.00 is trading 13.9% above its estimated GF Value™ of ₹2,815.72. GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.

Key valuation signals for NSE:NGLFINE:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹2,815.72 vs. price of ₹3,206.00 (13.9% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NGL Fine-Chem Business Description

Other Exchanges 524774:India
Address 301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score

Get the complete analysis for NSE:NGLFINE

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,206.00
Price
₹2,815.72
GF Value